Press Releases

May 21, 2020 at 8:30 AM EDT

Summary Toggle Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc.

PDF Version
May 8, 2020 at 9:30 AM EDT

Summary Toggle Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA (LUNAR-COV19) Induces Adaptive Cellular Immunity PRNT50 Value (Titers) After LUNAR-COV19 Vaccination STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional

PDF Version 271.9 KB
May 7, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains on track to begin clinical trial for COVID-19 vaccine this summer Successfully raised net of $75.5 million in secondary

PDF Version
May 4, 2020 at 3:00 PM EDT

Summary Toggle Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020 106.1 KB
May 4, 2020 at 8:39 AM EDT

Summary Toggle Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

SAN DIEGO and SOMERSET, N.J. , May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced

PDF Version
April 27, 2020 at 7:00 AM EDT

Summary Toggle Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

100% of animals seroconverted by day 19 at a low dose (2 µg) LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO , April 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger

PDF Version
April 21, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO , April 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the

PDF Version
April 16, 2020 at 9:10 AM EDT

Summary Toggle Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

SAN DIEGO , April 16, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the

PDF Version
April 15, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO , April 15, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it intends to

PDF Version
April 13, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO , April 13, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading clinical-stage

PDF Version